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tation of the low-binding F158 allele among patients who devel-The FcRIIIA-F158 allele is a risk factor for the development
oped renal disease [odds ratio (OR) 1.20, 95% confidenceof lupus nephritis: A meta-analysis.
interval (95% CI) 1.06 to 1.36, P  0.003)], without significantBackground. The FccRIIIA-V/F158 polymorphism affects
between-study heterogeneity. FF homozygotes had the highestimmunoglobulins (Ig)G1- and IgG3-binding capacity and may
risk of renal disease as compared to VV homozygotes (ORmodulate the expression of renal disease in patients with sys-
1.47, 95% CI 1.11 to 1.93, P 0.006). It was uncertain whethertemic lupus erythematosus (SLE). We aimed to determine
the F158 allele influenced susceptibility to SLE per se (ORwhether this polymorphism confers risk for the development
1.19, 95% CI 0.99 to 1.43, P  0.063 for SLE patients withoutof lupus nephritis and SLE in general.
nephritis versus disease-free controls; 0.01  P  0.10 forMethods. A meta-analysis was performed based on the Med-
heterogeneity) and the observed trend for an association wasline and Embase databases (last update, August 2002), perusal
driven mostly by the smaller studies (P 0.058 for publicationof abstracts from major meetings (1999 to 2001), assessment
bias). No such bias was detected for analyses on susceptibilityof bibliographies of pertinent articles, and additional data gath-
to lupus nephritis.ered after contact with primary investigators.
Conclusion. The FccRIIIA-V/F158 polymorphism has a sig-Results. A total of 16 comparisons from 11 studies involving
nificant impact on the development of lupus nephritis.V/F158 genotyping of 1154 patients with lupus nephritis, 1261
SLE patients without nephritis, and 1455 disease-free controls
were included. Comparison of lupus nephritis patients with
non-nephritis SLE subjects revealed a significant overrepresen- Genetic factors are considered crucial determinants
for susceptibility to and expression of systemic lupus
erythematosus (SLE) [1, 2]. The heritable basis for SLE1 These investigators contributed data and/or clarifications to the meta-
susceptibility and clinical expression probably dependsanalysis and reviewed the final manuscript: Masja de Haas, M.D., Ph.D.,
Central Laboratory of the Netherlands Red Cross Blood Transfusion on the interaction of many genes. Certain major histo-
Service and Department of Experimental Immunohematology, Univer- compatibility complex (MHC) class II alleles or homozy-
sity of Amsterdam, Amsterdam; and Academic Medical Centre; Amster-
gous complement deficiencies have been associated withdam, The Netherlands; Jeffrey C. Edberg, Ph.D., Department of Medi-
cine and Microbiology, University of Alabama at Birmingham, SLE [3]. Other polymorphic loci are also emerging as
Birmingham, Alabama, USA; Robert Kimberly, M.D., Department of potentially important in predisposition to lupus or dis-
Medicine and Microbiology, University of Alabama at Birmingham,
ease phenotype [3, 4]. Considerable information has ac-Birmingham, Alabama, USA; Harry R. Koene, M.D., Ph.D., Central
Laboratory of The Netherlands Red Cross Blood Transfusion Service cumulated on polymorphisms of the low-binding Fc
and Academic Medical Centre, University of Amsterdam, Amsterdam, receptor (FcR) genes, and especially for FccRIIA and
The Netherlands; Karin Manger, M.D., Department of Internal Medi-
FccRIIIA that encode molecules with differing functionalcine III and Institute for Clinical Immunology, University of Erlangen-
Nuremberg, Erlangen, Germany; Jane E. Salmon, M.D., Hospital for characteristics [5–8]. The effect of these polymorphisms
Special Surgery and New York Hospital, Cornell Medical Center, New on the handling of immune complexes in vivo might have
York, New York, USA; Naoyuki Tsuchiya, M.D., Ph.D., Department
implications particularly for lupus nephritis, the mostof Human Genetics, Graduate School of Medicine, University of Tokyo,
Tokyo, Japan; and Dae-Hyun Yoo, M.D., Ph.D., Hospital for Rheu- important manifestation of SLE that is related to immune
matic Diseases, Hanyang University, Seoul, Korea. complexes. The two allelic forms of FccRIIA differ by a
single amino acid at residue 131 (histidine [H] or arginineKey words: systemic lupus erythematosus, lupus nephritis, Fc recep-
tor; polymorphism, meta-analysis. [R]) and have markedly different binding properties for
human IgG2 [5]. In a recent international meta-analysisReceived for publication September 9, 2002
we have demonstrated that homozygosity for R131, theand in revised form October 22, 2002
Accepted for publication November 21, 2002 low-binging IgG2 allele of the FccRIIA gene, confers a
much higher level of risk for the development of SLE 2003 by the International Society of Nephrology
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compared with both other genotypes combined [9]. How- polymorphism in susceptibility to SLE and lupus nephri-
tis [9]. Briefly, we recorded type of study design, racialever, this polymorphism has no clear effect on suscepti-
bility for lupus nephritis [9]. Similarly FccRIIIA,which ancestry of the participants [European (including His-
panic), African, and Asian descent], selection of controlis expressed on mononuclear phagocytes and natural
killer cells, has two co-dominantly expressed alleles, group, criteria used for the diagnosis of SLE, definition
of nephritis, demographics of the study population, totalV158 and F158, that differ at amino acid position 158 in
the extracellular domain (often designated as 176V/F by sample size, and the number of SLE cases (total, with
and without nephritis) and control subjects for eachcounting from the first amino acid of the signal peptide)
[6, 10]. FccRIIIA allelic variants differ in IgG1 and IgG3 FccRIIIA genotype. We also examined whether it had
been specifically mentioned that personnel who per-binding; VV homozygotes bind IgG1 and IgG3 more
avidly than FF homozygotes [6, 10]. In case-control asso- formed the genotyping were blinded to the clinical status
of subjects, whether the genotyping method had beenciation studies performed in several ethnic groups, evi-
dence in support of a role for this polymorphism in sus- validated, and whether genotypes in the control group
were in Hardy-Weinberg equilibrium. Finally, when dataceptibility to lupus nephritis and SLE in general has
been controversial [6, 8, 11–21]. In most such studies, were reported in the same study separately for popula-
tions of the same racial descent yet different geographicalthe sample size has been limited and has precluded at-
taining firm conclusions. Therefore, a quantitative syn- location, the division of data was sustained.
thesis of the evidence using rigorous methods is necessary
Meta-analysis methods[22]. To address these issues, we conducted a comprehen-
sive international meta-analysis of all available studies The first set of analyses examined the relationship
between the FccRIIIA-F158 allele and susceptibility torelating the FccRIIIA-V/F158 polymorphism to the de-
velopment of lupus nephritis and SLE. lupus nephritis and/or SLE. Initially, we examined the
comparison between SLE with nephritis versus SLE
without nephritis. We planned a priori that if a statisti-
METHODS
cally significant difference was seen between these two
Identification and eligibility of relevant studies groups, then in order to evaluate whether the FccRIIIA-
F158 allele is associated with predisposition to SLE inWe sought all controlled studies that examined the
association of the FccRIIIA-V/F158 polymorphism with general (beyond nephritis), the most clear comparison
would be between SLE subjects without nephritis andSLE and/or lupus nephritis and were published in En-
glish, French, German, or Italian. Sources included Med- disease-free controls. Otherwise, the comparison of all
SLE cases versus controls would be more appropriateline and Embase (last search updated in August 2002).
The search was based on combinations of pertinent terms and better powered to detect differences.
The second set of analyses examined genotypes. The(“systemic lupus erythematosus,” “rheumatic diseases,”
“connective tissue disease,” “autoimmune disease,” “poly- following genotype contrasts were examined: FF versus
FV  VV combined; FF  FV combined versus VV; FFmorphism,” “allele,” “genetics,” “Fc receptor,” and “Fc
receptor”), as described previously [9]. Nonfamilial stud- versus FV; FF versus VV; and FV versus VV. The first
contrast corresponds to a recessive genetic effect of theies were eligible if they had determined the distribution
of FccRIIIA alleles in both SLE patients and a control F158 allele, the second contrast corresponds to a domi-
nant effect of this low-binding allele, and the other threegroup of disease-free subjects. Studies comparing the fre-
quency of FccRIIIA alleles among SLE patients with ne- contrasts probe into dose-response relationships. Geno-
type analyses were examined for the comparisons ofphritis and those without nephritis were also eligible. The
search was complemented with perusal of abstracts from groups found to be most appropriate on allele-based
analyses. The odds ratio (OR) was used as the metricmajor meetings in the last 3 years and by contact with
experts. We also communicated with the investigators of association, because these studies typically used case-
control designs.of original studies to obtain clarifications and additional
data beyond the published reports. Finally, the refer- The quantitative methods used in the meta-analysis
methods have been previously described in detail [9].ences of retrieved articles and of review articles were
screened for additional eligible studies. The contributing In brief, for each comparison and genetic contrast, we
estimated between-study heterogeneity using the chi-investigators were asked to comment on the final data
synthesis. square-based Q statistic [23]. Heterogeneity was consid-
ered significant for P  0.10. Study-specific data were
Data extraction combined using both fixed [24] and random effects [25]
models, the latter incorporating an estimate of the be-Two investigators independently extracted the data.
Data extraction followed the layout used in a previous tween-study variance. Unless stated otherwise, random
effects estimates are provided.meta-analysis examining the role of the FccRIIA-R/H131
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Table 1. Characteristics of studies included in the meta-analysis
Number of SLE patients F allele proportion
Year of Racial Analyzeda Non-SLE Non- Non-SLE
Reference publication Country ancestry Total (nephritis/non-nephritis) controls Nephritis nephritis controls
Wu et al [6] 1997 USA European 156 156 (59/97) 27 0.65 0.65 0.52
African 31 31 (10/21) 73 0.75 0.71 0.55
Asian 13 13 (10/3) 7 0.65 0.83 0.64
Koene et al [11] 1998 Netherlands European 70 70 (45/25) 87 0.73 0.76 0.57
Oh et al [12] 1999b USA African 77 72 (54/18) 73 0.53 0.53 0.56
Dijstelbloem et al [13] 2000 Netherlands European 230 230 (108/122) 154 0.64 0.63 0.67
Zuniga et al [14] 2001 USA European 67 67 (46/21) 53 0.73 0.50 0.53
Seligman et al [15] 2001 USA Europeanc 402 397 (133/264) — 0.64 0.55 —
Asian 101 100 (59/41) — 0.62 0.56 —
African 71 71 (35/36) — 0.59 0.54 —
Yun et al [16] 2001 Korea Asian 300 299 (142/157) 197 0.59 0.56 0.62
Kyogoku et al [17] 2002 Japan Asian 193 193 (115/78) 303 0.79 0.74 0.70
Lee et al [18] 2002 Korea Asian 145 145 (80/65) 75 0.81 0.76 0.73
Edberg et al [8] 2002d USA African 235 235 (108/127) 128 0.70 0.67 0.60
European 203 203 (95/108) 91 0.64 0.62 0.56
Manger et al [19] 2002 Germany European 140 133 (55/78) 187 0.65 0.61 0.53
a For systemic lupus erythematosus (SLE) patients that were analyzed, both genotype and clinical information was available
b In this study, a definition of nephritis was not provided; for the purposes of our analysis, we selected only patients with proteinuria
c In this study, data from Caucasian and Hispanic SLE patients were combined
d In this study, we used only data from the case-control cohort
Cumulative meta-analysis and recursive cumulative [30]. Only one report [12] recruited patients on the basis
of a clinical diagnosis of SLE, but 96% of them also metmeta-analysis [26–28] were used in order to evaluate
four or more of the ACR 1982 criteria. Two studies [8, 19]whether the combined OR changed over time as more
used the updated ACR criteria for the classification ofdata on each comparison and contrast were accumulated.
SLE [31], apart from the 1982 criteria. Seven studies [8,A publication bias diagnostic [29] examined whether
11, 13, 16–18] used the relevant ACR criterion for thesmall studies gave different results than large studies.
definition of renal disease. In three studies, certain labo-The diagnostic is considered significant for P 0.10 [29].
ratory findings, alone [12] or in common with specificSubgroup analyses estimated subgroup-specific ORs de-
histologic features on renal biopsy [14, 15], were usedfined by race. Subgroup estimates were tested for hetero-
to define renal damage and one report [6] did not clarifygeneity with the Q statistic. Analyses were conducted
its criteria.using SPSS version 10.0 (SPSS, Chicago, IL, USA) and
In five comparisons [6, 11, 12, 14, 17], patients withMeta-Analyst (Joseph Lau, Boston, MA, USA). P values
nephritis comprised60% of the total SLE cohort, indi-are two-tailed.
cating an over-recruitment of nephritis cases. In more
than one half of the comparisons, controls were consider-
RESULTS ably fewer than SLE cases (Table 1). No study indicated
whether the personnel who performed the genotypingCharacteristics of eligible studies
were blinded to the clinical status of the participants.Eighteen comparisons from 13 reports addressing the
In all the eligible reports, the genotyping method had
relationship between the FccRIIIA-V/F158 polymor-
previously been validated (N  6) or was validated dur-
phism and susceptibility to SLE and/or the development ing the study by sequencing (N  5).
of lupus nephritis were identified [6, 8, 11–21]. Two re- In total, 1154 SLE patients with nephritis, 1261 SLE
ports [20, 21] were excluded because of extensive over- patients without nephritis, and 1455 disease-free controls
lapping with other included studies. In addition, 13 pa- were included in the quantitative synthesis. The low-
tients labeled as “other” ethnicity (not specified) in one binding F158 allele was more highly represented among
study [15] were excluded from the analyses. Thus, the non-SLE controls of Asian descent than among those of
meta-analysis included 16 eligible comparisons [6, 8, other racial descent (Table 1). The study-specific fre-
11–19]; 13 of these comparisons [6, 8, 11–14, 16–19] had quencies were 0.52 to 0.67 in 599 non-SLE controls of
data evaluating the association between the FccRIIIA-V/ European descent [6, 8, 11, 13, 14, 19], 0.55 to 0.60 in
F158 polymorphism and predisposition to SLE and 16 274 controls of African descent [6, 8, 12], and 0.62 to
[6, 8, 11–19] had data on lupus nephritis versus SLE 0.73 in 582 controls of Asian descent [6, 16–18]. The
without nephritis (Table 1). distribution of genotypes in all disease-free control
In almost all studies, SLE patients fulfilled the revised groups was consistent with Hardy-Weinberg equilibrium
(all P values 0.05).American College of Rheumatology (ACR) 1982 criteria
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Table 2. Summary odds ratios (OR) for the association of systemic lupus erythematosus (SLE) or lupus nephritis with FcRIIIA specific
allele frequencies (random effects model)
F versus V
Comparison group No. of comparisons OR (95% CI) No. of alleles
SLE nephritis versus SLE without nephritis 16 1.20 (1.06–1.36) 4830
European descent 7 1.21 (1.00–1.46) 2512
African descent 4 1.14 (0.84–1.54) 818
Asian descent 5 1.22 (0.98–1.52) 1500
SLE without nephritis versus disease-free controls 13 1.19 (0.99–1.43)a 4750
European descent 6 1.26 (0.96–1.65)a 2100
African descent 3 1.34 (0.94–1.92) 880
Asian descent 4 1.01 (0.73–1.41) 1770
a 0.01  P  0.10 for heterogeneity
Meta-analysis heterogeneity in the relationship between the F158 allele
and SLE susceptibility, which also persisted within theOverall effects. Comparison of lupus nephritis patients
subgroup of subjects of European descent (Table 2). Inwith non-nephritis SLE subjects revealed a consistent
analyses of genotype contrasts, we encountered modestand overall statistically significant (P 0.003) over-repre-
heterogeneity in the contrast of FF versus FV  VV andsentation of the low-binding F158 allele among patients
prominent heterogeneity in the contrast of FF versus FV.who developed renal disease (Table 2; Fig. 1A). Thus,
There was no evidence that the magnitude of the ob-a comparison of SLE without nephritis against disease-
served association of F158 with lupus nephritis changedfree controls was considered most appropriate for exam-
substantially over time with the appearance of more stud-ining whether F158 confers additional predisposition to
ies. Early studies, published in 1997 and 1998, showedSLE per se. A modest trend for increased SLE suscepti-
some effect for SLE susceptibility that has constantlybility was noticed, but with significant between-study
decreased with the appearance of more recent studiesheterogeneity (Table 2; Fig. 1B).
(published between 1999 and 2002). There was also noRacial subgroup analyses. The FccRIIIA-F158 allele
suggestion that the observed association of F158 withwas similarly enriched among lupus nephritis patients in
lupus nephritis differed in small versus large studies (P all racial subgroups. Formal statistical significance was
0.32). Conversely, there was evidence that for the com-reached only in patients of European descent, where the
parison of SLE without nephritis versus disease-free con-largest amount of data was available (Table 2). The low-
trols, the largest studies showed no association at all,binding allele did not confer a significant risk for the
while small studies suggested an association, a situationdevelopment of SLE in any of the racial subgroups, but
that may be reflect publication bias against small studies
some trend was seen for subjects of European and Afri-
with “negative” results (P  0.058).
can descents.
Genotype contrasts. When genotype contrasts between
DISCUSSIONpatients with nephritis and those without nephritis were
analyzed, the largest, most clear effect for susceptibility In the present international meta-analysis, we docu-
to renal disease was observed for the contrast of homozy- mented the importance of common genetic variants of
gotes (FF versus VV; Table 3). Nevertheless, the data FcR that alter IgG binding capacity as disease-modi-
are consistent with either a recessive, or dominant, or fying genes in SLE. F158, the low-binding allele of the
dose-response model. For susceptibility to SLE, none of FccRIIIA gene, conferred a 1.2-fold greater risk for the
the contrasts shows any statistically significant effect, and development of renal disease among lupus patients. This
the findings are consistent with the possibility that the association seemed to be of similar magnitude in all racial
FccRIIIA-V/F158 polymorphism does not affect predis- subgroups. Conversely, we did not clearly document any
position to SLE in the absence of nephritis, but modest significant role for this polymorphism in susceptibility to
associations cannot be totally ruled out. SLE without nephritis, although a small effect cannot
Heterogeneity and bias diagnostics. There was no sig- be excluded.
nificant heterogeneity on allele-based associations of Impaired handling of antigen-antibody complexes in
F158 with lupus nephritis either overall or at the analyses SLE leads to their deposition in tissue and to organ
of racial subgroups. There was also no significant hetero- damage, particularly glomerulonephritis. The efficiency
geneity in any of the genotype contrasts for this compari- of the mononuclear phagocytes in removing circulating
son, except for modest heterogeneity in the case of FF immune complexes depends on FcR and receptors for
complement. Allelic variation of FcR alters the func-versus FV. Conversely, there was some between-study
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Fig. 1. Meta-analysis for effects of the Fcc
RIIIA-V/F158 polymorphism on the risk of
lupus nephritis (A ) and systemic lupus erythe-
matosus (SLE) (B ). Comparisons from indi-
vidual studies are shown. Af signifies African
descent, As signifies Asian descent; all other
comparisons are for subjects of European de-
scent. For each comparison, a point estimate
of the odds ratio (OR) and the accompanying
95% confidence interval (95% CI) are pre-
sented. Also shown is the summary OR estimate
(All) according to random effects calculations
highlighted with a vertical discontinuous ref-
erence line. Values 1 denote an increased
risk with the F158 allele. The continuous verti-
cal reference line corresponds to no associa-
tion (OR  1). Inspection of the results of
each study shows that the F158 allele was sig-
nificantly associated with renal involvement
in two comparisons [Seligman et al for subjects
of European descent (OR 1.40, 95% CI 1.03
to 1.89) and Zuniga et al (OR 2.68, 95% CI
1.25 to 5.73)], but all other studies, with two
exceptions, showed positive trends for such
an association. For susceptibility to SLE, only
one of the comparisons demonstrated a statis-
tically significant association with the low-
binding allele [Koene et al (OR 2.34, 95% CI
1.15 to 4.79)] and the remaining studies were
more evenly divided for showing positive or
negative trends.
Table 3. Summary odds ratios (OR) for the association of systemic lupus erythematosus (SLE) or lupus nephritis with FcRIIIA specific
genotypes (random effects model)
SLE nephritis versus SLE without nephritis SLE without nephritis versus disease-free controls
Comparison group No. of comparisons OR (95% CI) No. of subjects No. of comparisons OR (95% CI) No. of subjects
FF versus FV  VV 16 1.24 (1.01–1.52) 2415 13 1.32 (0.99–1.77)a 2375
VV versus FV  FF 15 0.79 (0.61–1.01) 2402 13 0.88 (0.65–1.18) 2375
FF versus FV 16 1.19 (0.91–1.54)a 2092 13 1.31 (0.96–1.80)b 2038
FF versus VV 15 1.47 (1.11–1.93) 1326 13 1.33 (0.93–1.90) 1273
FV versus VV 15 1.21 (0.87–1.67) 1399 13 1.03 (0.72–1.46) 1439
a 0.01  P  0.10 for heterogeneity; bP  0.01 for heterogeneity
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tional capacities of phagocytes and provides a mecha- free controls is that certain lupus patients carrying the
low-binding allele might have had relatively short diseasenism for heritable differences in susceptibility to immune
complex–mediated injury. Homozygosity for low-bind- duration prior to their inclusion in the relevant studies.
In that case, some of these who ultimately develop renaling alleles at either the FccRIIA or the FccRIIIA locus
can lead to impaired handling of immune complexes [7]. disease might have been misclassified as non-nephritis
patients. This would also result in a spurious effect ofNevertheless, the relative importance of each of these
genes on disease phenotype may depend on the IgG the F158 allele on SLE susceptibility per se.
The fact that low-affinity FccR genes are clustered insubclass of pathogenic autoantibodies. For example,
anti-C1q antibodies may manifest enhanced pathogenic- close proximity on chromosome 1 may suggest a linked
pattern of inheritance [42, 43]. The relative importanceity in lupus patients with inherited deficiencies in the
removal of IgG2-containing immune complexes [32, 33]. of possible epistatic interactions between alleles and the
potential role of linkage disequilibrium either amongOn the other hand, anti-double-stranded DNA and anti-
nucleosome antibodies, which mostly correlate with ne- FccR genes or between this cluster and other nearby
candidate genes are not yet well known. Some studiesphritis, belong largely to the IgG1 and IgG3 subclasses
[34–36]. Since the major IgG subclasses in immune de- that have examined haplotypes of FccRIIA-R/H131 and
FccRIIIA-V/F158 suggest that linkage disequilibriumposits of proliferative glomerulonephritis are also IgG1
and IgG3, rather than IgG2 [37, 38], FccRIIIA variants may exist between IIA and IIIA genes [8, 17, 44], but this
has not been demonstrated in all studied ethnic groupswould be expected to play a more prominent role in
lupus nephritis than FccRIIA alleles. Moreover, family- [14, 17]. There also appears to be a selection of the
R131-F158 haplotypes among SLE patients comparedbased association analyses demonstrated preferential
transmission of the FccRIIIA-F158 allele in SLE patients to controls [14, 19]. However, other studies [16] fail to
demonstrate such an overrepresentation. Linkage dis-with renal disease but no evidence for such association
at FccRIIA locus [8]. In accordance with these observa- equilibrium may further explain the observed weak trend
for an association of F158 with SLE. The trend maytions, we clearly demonstrated that among lupus patients
the presence of the F158 allele enhances the risk of renal reflect the indirect effect of the linked R131 allele that
is more definitively associated with SLE [9]. Other poly-involvement. Along the same lines, the FccRIIA-R131
allele that is associated with decreased IgG2 binding morphisms (e.g., the FccRIIIB-NA1/2 [7] and the re-
cently described FccRIIB-I/T232 polymorphism [17])influences SLE susceptibility but not lupus nephritis [9].
Given a risk ratio of 1.2, the proportion of lupus nephritis may also need to be taken into account. Preliminary
evidence suggests that both these loci are at weak linkagecases that could be attributed to the F158 allele (attribut-
able fraction) is estimated at approximately 10% to 14%, disequilibrium with FccRIIIA [17]. In some Caucasians,
the F158 allele seems to form haplotypes with thefor various populations with 50% to 70% prevalence of
this low-binding allele. As the outcome of the disease is FccRIIIB variants [17, 44]. Risk models including also
other, distant genes that have shown a potential associa-negatively influenced by nephritis [39], the FccRIIIA-V/
F158 polymorphism may also have a remarkable impact tion with lupus nephritis and its severity [45, 46] should
also be considered.on the overall prognosis of SLE patients.
World Health Organization (WHO) classes III and IV Some limitations of this study should be discussed.
First, publication bias is often cited as a problem in meta-of nephritis are characterized par excellence by immune
complex deposition and complement consumption. Thus, analyses [47]. We made meticulous efforts to identify all
relevant data and to obtain additional information fromthe F158 allele may influence proliferative (classes III
and IV) nephritis, but not necessarily membranous (class investigators and we also employed appropriate diagnos-
tic tests. It is unlikely that publication bias underlies theV) nephritis. However, the number of patients with renal
biopsy in eligible studies was too small to reliably analyze observed association between F158 and lupus nephritis.
Second, among the various specific manifestations ofsubgroups of patients with different forms of glomerulo-
nephritis. SLE, this meta-analysis specifically targeted lupus ne-
phritis. There are limited data on whether the FccRIIIA-Although we observed a trend that could imply an
effect of the F158 allele on SLE susceptibility beyond V/F158 polymorphism may also be associated with other
disease manifestations such as arthritis and/or serositisnephritis, this trend was derived unilaterally from small
studies. Most large studies showed no strong association. [13, 16], hematologic abnormalities [13, 19], or the pres-
ence of anti-double-stranded DNA [17]. It has also beenThis is a situation where publication bias may be sus-
pected [40, 41] (i.e., that small studies with “negative” suggested that SLE patients homozygous for the F158
allele may develop disease at a younger age than doresults have remained unpublished). The larger studies
may then provide a more reliable estimate. An alterna- subjects with the other genotypes [13, 17, 19]. Prelimi-
nary data on these issues need further validation in largertive explanation for the observed heterogeneity in the
comparison between SLE without nephritis and disease- studies.
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